SLC2A1 and epilepsy: Median age at debut was lower in the SLC2A1(+)-group (1.7 ± 1.7 versus 2.2 ± 2.2 years), and in the epilepsy group (1.8 ± 1.5 versus 2.7 ± 3.2 years).